Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm surprised there weren't more comments on this post and link. Very interesting. Someone spent a lot of time putting their timeline together.
This is what concerns me (among many other items). Just very amateurish in my view.
Ironically, I think big pharma is the only hope. If they partner/purchase buc it would most likely get fast-tracked. They managed to get their stuff approved in almost a rubber stamp manner.
That's been my key learning with all this. The little guy doesnt have much of a chance.
you know i just saw the same commercial and it made me want to puke thinking about how messed up the system is.
Provided it's not a train coming at you:)
My beloved Blackhawks have stunk lately. My Captain deserves better.
I do get the point...I often think of him as a classic example of a long hauler. I wonder if he's tried buc.
I’m considering reaching out as well.
Selling these at $150 is not viable and 10x over retroreflectors. Just no ROI.
Installation, as I mentioned, is interesting. They definitely need to speed up the process or states won’t be happy. Current technology actually is pretty quick and uses a plunge cut saw. Contractors move fast. Granted sometimes too fast but what I saw in the video is not going to work.
To my knowledge I don’t think any of the large volume manufacturers of pavement markers do installation. Figuring out how to make that profitable is a challenge. Contractors overhead is hard to beat when there’s nothing proprietary about the process.
Here's the real problem with all the "smart" technologies. University of Michigan and TxDOT have been doing this for years. On top of that many people don't know that one of the biggest players in highway safety is 3M. Obviously, well funded and well resourced. They have had a program called "Connected Roads" or something like that for several years. If they want to, they will stir the drink. End of story. So, you have to look at this as getting a small piece of the pie and not inventing the pie.
Perhaps Ken can do an e-connection.
I am not well versed in many things but this one I am! I worked for the company that invented the snowplowable marker and have patents on variations. Also worked on LED delineation. Was on ASTM committees for specs. Installed markers. Worked with DOT across the country.
I’d love to help out. As I mentioned, it’s ok if there’s no patent protection. You can still be successful. It’s about having a business strategy that aligns with the reality of the industry.
Lastly, people shouldn’t compare overhead lighting with these LED pavement markers. The comparison should be lifespan costs of LED vs retroreflectors.
I don’t know the details regarding his sole source claim. I’m not here to bash him. I will say that seems odd and counter to how the bid process usually works. I can guarantee you that if they achieved sole source in one municipality or even state that it won’t transfer across to other states.
If I understand the reference to the “flush” need it’s the paradox of the product. It actually needs to be angled for the water and tire to clean the product. Otherwise it gets grime build up, so more of an issue for something relying on solar power. Back in the day we were focused on using special battery technology. With the progress in that area I’m surprised there isn’t more focus on it.
Also, he mentioned moving from one to three LED to get wider coverage. I’d have to rewatch more carefully but smart use of optics will spread the light where you need it - same as a car taillight. Also, it was hard to tell from the website but the projected area where the LED was housed looks vertical which again wouldn’t be conducive to staying clean. Again, it might be fine just hard to tell from picture.
His comment on installation was a bit sophomoric. Installing 2000 isn’t like installing 200000. If installed properly, the old iron ones simply do not come out. In fact, the epoxy is stronger than the asphalt. Usually the crew has not offset the casting from the crown of the road properly and the asphalt breaks up along the seam. Concrete is a different story. If this company is going to own the installation then they can control it. That’s not a bad model as the installation made millionaires out of some shrewd contractors instead of the OEM.
Like I said, the company could do well but nothing special about the product. Not sure if the presenter is that knowledgeable in the workings of the industry but it could be the audience he had to convince.
I appreciate everyone being excited but this company doesn’t have anything novel. The retroreflector industry is more competitive now because all the important patents have expired. The industry was cleverly built on ASTM standards around the patents of the pioneers. Without that it becomes pretty much a bid process and you can only bid for the state projects after getting approval. They do have the made in America thing going but California has some companies making similar products already.
I’m not saying this company can’t succeed. It’s just looking at the business realistically. Nothing special.
If Ken reads this and wants to reach out to me, please do. I would love to be on the advisory board for this one. I spent almost 15 years in this industry,been an expert witness, have patents in the field, blah blah blah.
The liquidity events just aren't happening. At this point, I'm more interested to see if they've been able to maintain momentum and trajectory with the payment platform. That is true revenue coming in.
I am willing to give the benefit of the doubt. However, transparency does include addressing when initiatives aren’t running to plan…IMO
I’d like Ken to acknowledge that the summer didn’t yield the anticipated results for liquidity events and provide guidance on the new target.
Yep, I don't anticipate any earth shattering news. I hope I'm wrong.
Thanks. I’m not looking to debate either. I appreciate you verifying what I thought I heard. We shall see if any PRs drop ahead of the podcast.
I will try to be available for the live version. I think most people consider summer over when Labor Day arrives. Been very quiet summer from a PR standpoint IMO.
I believe Ken thought the summer would include a liquidity event. Doesnt seem like that’s going to happen. I know there’s no guarantees but it’s disappointing.
Please correct me if I am not remembering this correctly.
I’ve been taught a lesson on this one. I got in at .17 and out at .76. Glad I wasn’t greedy. Bought back in at .13 thinking it couldn’t go any lower. Boy was I wrong. I’ve learned that having IP and good scientists means little without quality executive leadership that can maximize shareholder value.
I will watch this continue to fall and sell for tax break at EOY.
Perfectly put.
Why would anyone buy in to this? If you really do believe it will turn around you should wait because it’s going to keep dropping. Why wouldn’t it?
I thought they severed ties with Tom but he’s listed for Investor Relations.
Is this just careless or is he still in the fold?
Quick review shows they are cash poor —- like many small biotech companies. They might be forced to do another equity offering to finance the testing.
Nice to see revenue go up 300% versus 2021.
Curious what people are expecting in the financials? No revenue at this point.
Always appreciate Ecomike talking sense to me.
This has been a painful process.
This has been a painful process.
This has been a painful process.
This has been a painful process.
This has been a painful process.
…I know. We wait.
Are people really making fun of the CEO for having issues with the podcast? Who cares? I don't want him being an expert in podcasts. I want him focused on providing the vision and making sure it gets executed.
Anecdotally, I was in the office yesterday and we were trying to have a hybrid meeting. We had 6 IT guys (Directors and up) in the meeting and we ended up having to call a worker-bee in to show us how to do it. Happens all the time.
Worry about what's important.
I think it's going to be a challenge with the flippers. If you bought a bunch down at .0015 you doubled your money and got out. We are going to be battling this all the way to .05.
Can't wait to be on a big board.
Thanks. I got the same feeling. I also don't like the fact that there was no timeline given.
A little help with this news release...does it mean that they need to continue the study to gather additional data points?
Just a little confused by "the Company will now amend the Study protocol with the proposed new primary efficacy endpoints and submit to the FDA for further discussion and agreement."
Thanks for any clarification from the smart folks out there.
Thanks for confirming. I find that really encouraging. Hopefully we get an update on if they are on pace with customer onboarding.
Revenue was only for about a month, correct? Didn't they roll out the new service in May?
I would like to see if the revenue from Quadramune has increased over previous quarters.
Leadership shouldn't underestimate the value of transparency.
It’s difficult when no start date is provided for the Phase 3 study. I don’t see how Mr. Dixon thinks that is a good idea.
We only have another month of summer. I believe Ken had said that by summer's end there would have been movement in one or more of the liquidity events. Can someone confirm?
I don't want to spread inaccurate information.
Nope. But have several patents myself (non biotech) and been involved in both sides of litigation. So just going off of that experience and postulating on outcomes. Maybe there’s an actual lawyer on the board who can give us his/her insights.
Having strong IP is always great but keep in mind that a patent can be “worked around”. You’d like to think Charles has solid chops in writing the patent based on his background and experience so circumventing probably not as likely.
Enzc hasn’t shown the ability to get anything to market so unlikely to produce a revenue stream if they hold it tight.
Possible BP infringes and dares litigation response but most likely they see that ENZC would take a licensing agreement and that’s best case scenario IMO.
Who said anything about disclosing data? I want confirmation and transparency of the actual start date and where they are in recruiting. You know, like a normal biotech trial.
I have to say I’ve been following this company for a year. Using product for six months. Really like the pipeline. However, I can’t throw money at them until I see more transparency. Not being more forthcoming regarding phase 3 is a dealbreaker for now.
It’s interesting with biotech pinks…I see some companies with promising pipelines but often times have brilliant scientists in charge who don’t have the necessary CEO skills.
Agree with you. Like some others I really didn’t get much from today’s PR. I would have liked more concrete dates or at least better guidance than…”statistician team is currently analyzing the Data and the Company aims to submit the amended Study protocol to the FDA shortly thereafter”
I understand they can’t control the pace of FDA but I would think they can control the pace of their own analysis.
Obviously we want the analysis thoroughly done but I think some guardrails on timing is still possible. Oh well…we wait some more. Fingers crossed.